To further study the effects of MAPK activation and imatinib resistance, we generated K562 SPRED2 KO and SPRED2 overexpression cell lines (SPRED2 KO and SPRED2+, respectively) to investigate the potential therapeutic benefit of targeting MAPK signaling in CML SPRED2 KO was obtained through dual sgRNA cleavage and efficient at 88.9%, whereas SPRED2 overexpression was obtained through lentiviral transduction. The gene discussed is SPRED2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.